Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 2
1973 1
1974 4
1975 5
1976 4
1977 9
1978 8
1979 18
1980 19
1981 18
1982 16
1983 15
1984 12
1985 28
1986 26
1987 13
1988 17
1989 25
1990 26
1991 19
1992 17
1993 17
1994 13
1995 9
1996 11
1997 11
1998 23
1999 17
2000 27
2001 24
2002 18
2003 28
2004 24
2005 28
2006 32
2007 32
2008 52
2009 26
2010 22
2011 20
2012 18
2013 19
2014 16
2015 9
2016 10
2017 9
2018 9
2019 8
2020 9
2021 7
2022 8
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

837 results

Results by year

Filters applied: . Clear all
Page 1
Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke.
Redman AR, Ryan GJ. Redman AR, et al. Expert Opin Pharmacother. 2004 Jan;5(1):117-23. doi: 10.1517/14656566.5.1.117. Expert Opin Pharmacother. 2004. PMID: 14680441 Review.
The long-term goal of therapy is to prevent the recurrence of stroke and other atherosclerotic events. Aspirin has been the first-line agent for stroke prevention for a long time. As new antiplatelet agents have been introduced, their role in the secondary prevention of st …
The long-term goal of therapy is to prevent the recurrence of stroke and other atherosclerotic events. Aspirin has been the first-lin …
Aggrenox: a fixed-dose combination of aspirin and dipyridamole.
Lenz TL, Hilleman DE. Lenz TL, et al. Ann Pharmacother. 2000 Nov;34(11):1283-90. doi: 10.1345/aph.10079. Ann Pharmacother. 2000. PMID: 11098344 Review.
The ESPS-1, however, did not include an aspirin-only treatment arm. Therefore, it was unclear whether the combination of aspirin/dipyridamole was superior to aspirin alone. ...However, with the favorable results of the ESPS-2, it may be appropri …
The ESPS-1, however, did not include an aspirin-only treatment arm. Therefore, it was unclear whether the combination of as
Aggrenox-associated acute interstitial nephritis.
Al Hwiesh A. Al Hwiesh A. Saudi J Kidney Dis Transpl. 2006 Mar;17(1):50-3. Saudi J Kidney Dis Transpl. 2006. PMID: 17297537
Acute interstitial nephritis (AIN) associated with the administration of the combination drug Aggrenox ( acetylsalicylic acid 25 mg and dipyridamole 200 mg) has not been previously reported. ...In conclusion, this patient suffered AIN associated with t …
Acute interstitial nephritis (AIN) associated with the administration of the combination drug Aggrenox ( acetylsalicyli …
A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection.
Singla A, Dadario NB, Singla A, Greenberg P, Yan R, Nanda A, Boison D, Malhotra R, Patel S, Nipun S, Maninderpal K, Castro D, Bdiiwi S, Boktor H, Kyi HH, Sutherland A, Patrawalla A, Ly K, Xie Y, Sonig A, Khandelwal P, Liu J, Koziol J, Finkle D, Subanna S, Libutti SK. Singla A, et al. PLoS One. 2023 Jan 30;18(1):e0274243. doi: 10.1371/journal.pone.0274243. eCollection 2023. PLoS One. 2023. PMID: 36716303 Free PMC article. Clinical Trial.
Likewise, low-dose aspirin has also demonstrated protective effects for COVID-19 patients. This study evaluated the effect of these two drugs formulated together as Aggrenox in hospitalized COVID-19 patients. METHODS: In an open-label, single site randomized control …
Likewise, low-dose aspirin has also demonstrated protective effects for COVID-19 patients. This study evaluated the effect of these t …
Aggrenox: an aspirin and extended-release dipyridamole combination.
Wong NN. Wong NN. Heart Dis. 2001 Sep-Oct;3(5):340-6. doi: 10.1097/00132580-200109000-00011. Heart Dis. 2001. PMID: 11975816
At this point, much of the pharmacologic information concerning this combination agent is based on previous data about aspirin and immediate-release dipyridamole. This combination of aspirin and extended-release dipyridamole may play a si …
At this point, much of the pharmacologic information concerning this combination agent is based on previous data about aspirin
Aggrenox (Asasantin retard)-induced Stevens-Johnson syndrome.
Jao T, Tsai TH, Jeng JS. Jao T, et al. Br J Clin Pharmacol. 2009 Feb;67(2):264-5. doi: 10.1111/j.1365-2125.2008.03340.x. Epub 2008 Dec 16. Br J Clin Pharmacol. 2009. PMID: 19094159 Free PMC article. No abstract available.
Aggrenox and stress testing.
Bergmann SR. Bergmann SR. Circulation. 2001 Feb 27;103(8):E50. doi: 10.1161/01.cir.103.8.e50. Circulation. 2001. PMID: 11222491 No abstract available.
Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial.
Serebruany VL, Malinin AI, Sane DC, Jilma B, Takserman A, Atar D, Hennekens CH. Serebruany VL, et al. Eur J Pharmacol. 2004 Sep 24;499(3):315-24. doi: 10.1016/j.ejphar.2004.07.114. Eur J Pharmacol. 2004. PMID: 15381054 Clinical Trial.
The European Stroke Prevention Study showed greater stroke prevention for Aggrenox than either for aspirin or dipyridamole alone. To test whether Aggrenox has superior antiplatelet properties to aspirin alone we conducted the AGgrenox ver …
The European Stroke Prevention Study showed greater stroke prevention for Aggrenox than either for aspirin or dipyridamole
Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial.
Dixon BS, Beck GJ, Dember LM, Depner TA, Gassman JJ, Greene T, Himmelfarb J, Hunsicker LG, Kaufman JS, Lawson JH, Meyers CM, Middleton JP, Radeva M, Schwab SJ, Whiting JF, Feldman HI; DAC Study Group. Dixon BS, et al. Clin Trials. 2005;2(5):400-12. doi: 10.1191/1740774505cn110oa. Clin Trials. 2005. PMID: 16317809
BACKGROUND: Surgically created arteriovenous (AV) grafts are the most common type of hemodialysis vascular access in the United States, but fail frequently due to the development of venous stenosis. The Dialysis Access Consortium (DAC) Aggrenox Prevention of Access Stenosi …
BACKGROUND: Surgically created arteriovenous (AV) grafts are the most common type of hemodialysis vascular access in the United States, but …
Rapid platelet inhibition after a single capsule of Aggrenox: challenging a conventional full-dose aspirin antiplatelet advantage?
Serebruany VL, Malinin AI, Sane DC. Serebruany VL, et al. Am J Hematol. 2003 Apr;72(4):280-1. doi: 10.1002/ajh.10290. Am J Hematol. 2003. PMID: 12666142 Free article. Clinical Trial.
Aggrenox is a novel combination of 25 mg of aspirin with 200 mg of sustained release dipyridamole. In a recent large trial (ESPS-2), Aggrenox was twice as effective for secondary stroke prevention as either aspirin or dipyridamole
Aggrenox is a novel combination of 25 mg of aspirin with 200 mg of sustained release dipyridamole. In a recent l
837 results